Aura Biosciences (AURA) reported a Q2 loss Tuesday of $0.48 per diluted share, compared with a loss of $0.47 a year earlier.

A single analyst polled by FactSet expected a loss of $0.38.

The company had $323.8 million in cash, cash equivalents and marketable securities as of June 30, which it expects will fund operations into H1 2029.

Shares of the company declined around 1% in premarket activity Tuesday.